Artivion, Inc. (NYSE:AORT) Shares Sold by Mesirow Financial Investment Management Inc.

Mesirow Financial Investment Management Inc. decreased its holdings in Artivion, Inc. (NYSE:AORT) by 17.9% in the 3rd quarter, Holdings Channel reports. The firm owned 10,485 shares of the company’s stock after selling 2,289 shares during the period. Mesirow Financial Investment Management Inc.’s holdings in Artivion were worth $279,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently bought and sold shares of AORT. nVerses Capital LLC purchased a new position in shares of Artivion in the 2nd quarter valued at approximately $28,000. RiverPark Advisors LLC acquired a new stake in shares of Artivion during the second quarter worth $55,000. Allspring Global Investments Holdings LLC grew its position in Artivion by 291.3% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 5,580 shares of the company’s stock valued at $118,000 after buying an additional 4,154 shares during the last quarter. RW Investment Management LLC purchased a new position in Artivion during the 2nd quarter worth $219,000. Finally, Intech Investment Management LLC purchased a new position in Artivion during the 2nd quarter worth $253,000. Institutional investors and hedge funds own 86.37% of the company’s stock.

Artivion Stock Performance

Shares of AORT stock opened at $27.71 on Wednesday. The company has a debt-to-equity ratio of 1.07, a quick ratio of 4.04 and a current ratio of 5.63. The stock has a market cap of $1.16 billion, a PE ratio of -1,432.00 and a beta of 1.75. Artivion, Inc. has a 1 year low of $13.18 and a 1 year high of $30.00. The stock has a fifty day moving average price of $26.23 and a 200 day moving average price of $25.24.

Insider Transactions at Artivion

In related news, CAO Amy Horton sold 12,430 shares of Artivion stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $26.18, for a total transaction of $325,417.40. Following the completion of the sale, the chief accounting officer now owns 139,989 shares in the company, valued at approximately $3,664,912.02. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Artivion news, CAO Amy Horton sold 12,430 shares of the stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $26.18, for a total transaction of $325,417.40. Following the transaction, the chief accounting officer now owns 139,989 shares of the company’s stock, valued at $3,664,912.02. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Jean F. Holloway sold 2,383 shares of Artivion stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $25.76, for a total value of $61,386.08. Following the completion of the sale, the senior vice president now directly owns 165,099 shares of the company’s stock, valued at approximately $4,252,950.24. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 27,400 shares of company stock valued at $709,308 in the last 90 days. 8.10% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

AORT has been the topic of a number of recent analyst reports. Needham & Company LLC reiterated a “buy” rating and set a $30.00 price target on shares of Artivion in a research note on Friday, September 27th. Oppenheimer boosted their target price on Artivion from $30.00 to $32.00 and gave the stock an “outperform” rating in a research report on Friday, November 8th. Stifel Nicolaus raised their price target on Artivion from $28.00 to $30.00 and gave the company a “buy” rating in a report on Friday, September 13th. Finally, JMP Securities began coverage on Artivion in a report on Wednesday, October 23rd. They set an “outperform” rating and a $33.00 price objective on the stock. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Artivion presently has an average rating of “Buy” and a consensus price target of $31.00.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.